| Donna R Merideth, RPH | |
|
211 S 1st St, Alpha, IL 61413-5152 | |
| (309) 629-4506 | |
| (309) 629-2611 |
| Full Name | Donna R Merideth |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 211 S 1st St, Alpha, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023604758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051039108 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Donna R Merideth, RPH Po Box 355, Alpha, IL 61413-0355 Ph: (309) 629-4506 | Donna R Merideth, RPH 211 S 1st St, Alpha, IL 61413-5152 Ph: (309) 629-4506 |
News Archive
IRIN examines how a recent resolution to create an agency to promote women's "rights and wellbeing" by the U.N. General Assembly is being welcomed by international HIV/AIDS advocates. According to IRIN, "[w]omen make up 60 percent of people living with AIDS in sub-Saharan Africa, a figure that rises to 75 percent in the 15-24 age range. In Asia, nearly 50 million women are at risk of becoming infected with HIV from their partners."
According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35. Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks. A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
Researchers at Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh School of Medicine have developed and refined a blood test that could help clinicians identify infants who may have had bleeding of the brain as a result of abusive head trauma, sometimes referred to as shaken baby syndrome.
› Verified 8 days ago
Mr. John C Lewis, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 1st St S, Alpha, IL 61413 Phone: 309-629-4506 Fax: 309-629-2611 |